The identification of pathogenic variants in genes such as BRCA1 and BRCA2 is essential for guiding prevention and clinical management. However, variants of uncertain significance (VUS) remain a major challenge, limiting decision-making regarding surveillance, risk-reducing strategies, and family testing. Although inte...
Túlio de Lima Campos, B. F. Nascimento, Paula Francinete Faustino da Silva et al.· Mastology· 0 citations
The reclassification of VUS demonstrated a direct impact on genetic interpretation and risk stratification in patients with breast cancer, and the identification of likely pathogenic variants reinforces the importance of appropriate clinical follow-up for patients and their families.
J. F. Tavares, Paula Francinete Faustino da Silva, B. F. Nascimento et al.· Mastology· 0 citations
Introduction: Breast cancer is the most common malignancy among women, with 5–10% of cases arising from hereditary predisposition, driven by pathogenic variants in DNA repair genes such as BRCA1/BRCA2, as well as moderate-risk genes, including ATM, CHEK2, TP53, BARD1, and BRIP1. Next-generation sequencing improves vari...
B. F. Nascimento, I. M. Calassa, Luiz Henrique Alves Costa et al.· Mastology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.